TrialBritish journal of haematology2017

Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.

Shaji Kumar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.